salmeterol xinafoate has been researched along with Asthenia in 1 studies
salmeterol : A racemate consisting of equal parts of (R)- and (S)-salmeterol. It is a potent and selective beta2-adrenoceptor agonist (EC50 = 5.3 nM). Unlike other beta2 agonists, it binds to the exo-site domain of beta2 receptors, producing a slow onset of action and prolonged activation.
2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol : A phenol having a hydroxymethyl group at C-2 and a 1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl group at C-4; derivative of phenylethanolamine.
Asthenia: Clinical sign or symptom manifested as debility, or lack or loss of strength and energy.
| Excerpt | Relevance | Reference |
|---|---|---|
| " It had lower oral absorption and bioavailability than salmeterol in both rat and dog." | 1.37 | The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating a urea group. ( Barrett, VJ; Ford, AJ; Looker, BE; Lunniss, GE; Needham, D; Procopiou, PA; Smith, CE; Somers, G, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Procopiou, PA | 1 |
| Barrett, VJ | 1 |
| Ford, AJ | 1 |
| Looker, BE | 1 |
| Lunniss, GE | 1 |
| Needham, D | 1 |
| Smith, CE | 1 |
| Somers, G | 1 |
1 other study available for salmeterol xinafoate and Asthenia
| Article | Year |
|---|---|
The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating a urea group.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Asthenia; Bronchodilator Agents; CHO Cells; | 2011 |